Most Impactful Neurology Trial Readouts From Early 2025

In the first half of 2025, the neurology field has seen a wave of major clinical trial readouts that may shape the future of care across multiple disease areas. From pivotal phase 3 results in Alzheimer disease (AD) and migraines to promising data in rare neuromuscular and autoimmune disorders, the latest findings could redefine treatment possibilities and advancing precision medicine in neurology. These readouts have garnered widespread attention from clinicians and researchers alike, offering critical insights into therapeutic efficacy, safety, and trial design innovation.